| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +4 more
Date of Report (Date of earliest event reported): November 12, 2026 |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025 |
| 23 Oct 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On October 21, 2026, Akebia Therapeutics, Inc. (the “Company”) received a deficiency letter (the "Notice") from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the... |
| 14 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 7, 2026, Nicholas Grund, Senior Vice President and Chief Commercial Officer of Akebia Therapeutics, Inc. (the “Company”), notified the Company of his decision to resign his employment with the Company for personal reasons. His... |
| 10 Aug 2026 |
Form 4: Butler John P., Director
Received 350,000 shares by exercise or conversion ($221K) |
| 05 Aug 2026 | S-8 |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million; more than 10,500 patients now on therapy |
| 01 Jul 2026 |
Form 4: Ostrowski Erik, SVP, CFO, CBO & Treasurer
Sold 56,019 shares ($62.2K) |
| 30 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA |
| 29 Jun 2026 | 144 |
| 22 Jun 2026 |
Form 4: Wolf Myles, Director
Received 35,700 shares as a grant or award · Granted 53,600 Stock Option (Right to buy) |
| 22 Jun 2026 |
Form 4: Smith Cynthia, Director
Received 35,700 shares as a grant or award · Granted 53,600 Stock Option (Right to buy) |
| 22 Jun 2026 |
Form 4: Rogers Michael W, Director
Received 35,700 shares as a grant or award · Granted 53,600 Stock Option (Right to buy) |
| 22 Jun 2026 |
Form 4: Frieson Ron, Director
Received 35,700 shares as a grant or award · Granted 53,600 Stock Option (Right to buy) |
| 22 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2026, Akebia Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") to consider and vote upon the matters listed below. The following is a summary of the matters voted on at the... |
| 22 Jun 2026 |
Form 4: Zumwalt Leanne M, Director
Received 35,700 shares as a grant or award · Granted 53,600 Stock Option (Right to buy) |
| 22 Jun 2026 |
Form 4: Adams Adrian, Director
Received 35,700 shares as a grant or award · Granted 53,600 Stock Option (Right to buy) |
| 12 May 2026 | SCHEDULE 13G |
Loading...